EP PerMed Joint Transnational Call (JTC) 2026
The European Partnership for Personalised Medicine, EP PerMed, publishes a funding call for Personalised Medicine for CARdiovascular, MEtabolic, and kidNey diseases (CARMEN2026)
EP PerMed is a platform for joint programming of national and European regional research and innovation supporting activities putting into action “The Strategic Research & Innovation Agenda (SRIA) for Personalised Medicine (2023)” through dedicated research, development and innovation funding.
EP PerMed launched the joint transnational call 2026 (JTC2026) “Personalised Medicine for CARdiovascular, MEtabolic, and kidNey diseases” (acro-nym: CARMEN2026), co-funded by the European Union, to fund multinational, innovative research projects in personalised medicine (PM), which should bring together academic, clinical/public health and private research teams, thus enhancing the competitiveness in Europe and beyond in this field. The JTC2026 will be conducted simultaneously by the participating funding organisations in their respective region/country and coordinated centrally by the Joint Call Secretariat (JCS), hosted by the French National Research Agency, (ANR), FRANCE.
The call will be implemented in two stages, i.e. a pre- and a full proposal phase. The available budget for this call is 38 Mio. € (approx.).
Full details can be found here.
Planning to apply?
The VPH team is happy to be involved in your applications in a supporting role, taking on tasks related to consortium building, stakeholder outreach, communication, dissemination, social sciences, regulatory science and policy.
